Data Presentation of Bimekizumab Efficacy & Safety Versus Risankizumab In Patients With Active Psoriatic Arthritis: Results From A Head-to-head, Multicentre, Randomised, Phase 3b Study (BE BOLD)

Join us virtually to a briefing on the occasion of the results presentation from a head-to-head, multicentre, randomised, Phase 3b study (BE BOLD) at EULAR

Monday 8 June 2026 at 8:00am (EDT) – 1:00pm (BST) – 2:00pm (CEST)

The videoconference webcast (including a Q&A session) will be hosted by:

Emmanuel Caeymaex : Executive Vice President, Head of Patient Evidence (UCB)

Professor Iain McInnes: Vice Principal and Head of the College of Medical, Veterinary and Life Sciences at the University of Glasgow Research and Contact Dermatitis

Professor Joe Merola: President of the Psoriasis & Psoriatic Arthritis Clinics Multicenter Advancement Network Consortium, President of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis

Click here to register 

For any additional details or questions, do not hesitate to contact us at Investor-Relations@ucb.com.